#Australia #LabConnect #Clinical Trials #Port Melbourne #ACL

New Strategic Partnership Between LabConnect and ACL Specialised Trials

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have recently entered into a strategic partnership aimed at expanding clinical trial support across Australia and the Asia-Pacific region. This exclusive, multi-year agreement unites the strengths of both organizations to better serve the rising demand for clinical trial support from pharmaceutical, biotechnology, and clinical research organizations.

As a prominent player in the field, ACL Specialised Trials manages a wide range of clinical trials from Phase 1 through Phase 4 across its vast network of laboratories throughout Australia. With years of experience, ACL Specialised Trials is dedicated to delivering comprehensive pathology solutions and a variety of central laboratory services essential to both national and multi-site clinical trials.

Melinda McGrath, ACL Group Executive CEO, expressed her enthusiasm about the partnership, stating, "This long-term collaboration will provide global clients with unprecedented access to Australian patients, allowing us to bring significant international trials to the region. This not only enhances our capabilities but also has the potential to introduce essential medical breakthroughs that are vital for patient outcomes."

The partnership strengthens ACL's role in a rapidly growing market, which is projected to reach $8 billion. McGrath emphasized the importance of showcasing ACL’s expertise and dedicated team on an international stage.

LabConnect brings its wealth of experience as a central laboratory solutions provider, which will be enhanced by ACL's extensive range of testing services. The partnership emphasizes coordinated efforts including in-country lab kit building, biospecimen management, and logistics support. Catherine Osborne, the APAC General Manager at LabConnect, is spearheading the business operations to ensure that the partnership maximizes its potential.

The dedicated laboratory services provided by ACL will serve as a crucial hub for LabConnect's operations in this region, allowing for a seamless combination of resources and expertise. Wes Wheeler, the CEO of LabConnect, notes, "As more Asian Pacific investigative sites become integral to our clients' clinical development plans, our partnership with ACL Specialised Trials enables us to deliver top-notch laboratory services across this dynamic region."

About ACL Specialised Trials

ACL Specialised Trials is a vital part of Australian Clinical Labs, focused on enhancing patient lives through advancements in medical excellence and innovative technology. The subsidiary is particularly committed to supporting Phase I-IV clinical trials, and boasts a state-of-the-art facility backed by a team of skilled professionals to ensure patient-focused outcomes.

Visit specialisedtrials.com.au for more information and follow their advancements on LinkedIn.

About LabConnect

LabConnect stands as one of the most agile partners in central laboratory solutions, providing customized and scalable services for diverse clinical trials, regardless of complexity. With over 20 years in the industry and more than 1,900 studies across 93 countries, LabConnect serves as a trusted ally for entities involved in the fields of biotechnology, pharmaceutical research, and clinical trials.

LabConnect is dedicated to maintaining a modern approach, fostering strategic alliances with leading laboratories worldwide to facilitate access to continuous innovations and automation in clinical trials. Comprehensive services include custom lab kits, sample tracking, logistics, standardized sample processing, and a significant array of validated assays.

To learn more about LabConnect’s offering, visit labconnect.com and follow them on LinkedIn.